Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume – Should You Buy?

Shares of Pharvaris N.V. (NASDAQ:PHVS) saw strong trading volume on Friday . 686,686 shares traded hands during trading, an increase of 189% from the previous session’s volume of 237,227 shares.The stock last traded at $30.92 and had previously closed at $31.63.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. UBS Group set a $74.00 target price on shares of Pharvaris in a research note on Wednesday, May 13th. Wolfe Research started coverage on shares of Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Citizens Jmp dropped their target price on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. Finally, Citigroup reiterated a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $49.18.

Pharvaris Trading Down 1.7%

The firm has a market capitalization of $2.03 billion, a P/E ratio of -9.78 and a beta of -2.35. The company has a 50 day simple moving average of $29.14 and a two-hundred day simple moving average of $27.28.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, sell-side analysts expect that Pharvaris N.V. will post -3.25 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Berndt Modig sold 2,292 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $29.22, for a total value of $66,972.24. Following the sale, the chief executive officer directly owned 137,500 shares in the company, valued at approximately $4,017,750. The trade was a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Anna Nijdam sold 5,501 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $30.74, for a total value of $169,100.74. Following the transaction, the insider directly owned 48,945 shares of the company’s stock, valued at approximately $1,504,569.30. The trade was a 10.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 209,948 shares of company stock worth $6,268,141. 11.84% of the stock is owned by corporate insiders.

Institutional Trading of Pharvaris

Hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in shares of Pharvaris during the 4th quarter valued at approximately $35,000. JPMorgan Chase & Co. increased its position in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Pharvaris during the third quarter valued at $75,000. Barclays PLC bought a new position in Pharvaris during the fourth quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Pharvaris during the fourth quarter valued at $86,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.